MaxCyte, Inc.
MXCT
$2.61
$0.062.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.69M | 8.16M | 10.43M | 11.34M | 15.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.69M | 8.16M | 10.43M | 11.34M | 15.67M |
| Cost of Revenue | 2.28M | 1.93M | 1.49M | 1.40M | 1.57M |
| Gross Profit | 6.41M | 6.24M | 8.94M | 9.94M | 14.09M |
| SG&A Expenses | 13.68M | 13.95M | 14.26M | 14.47M | 15.28M |
| Depreciation & Amortization | 1.02M | 1.02M | 1.03M | 1.07M | 1.06M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.59M | 22.22M | 22.40M | 23.62M | 23.76M |
| Operating Income | -12.90M | -14.05M | -11.97M | -12.28M | -8.10M |
| Income Before Tax | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| EBIT | -12.90M | -14.05M | -11.97M | -12.28M | -8.10M |
| EBITDA | -11.84M | -12.99M | -10.89M | -11.16M | -6.99M |
| EPS Basic | -0.10 | -0.11 | -0.09 | -0.09 | -0.05 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.06 | -0.06 | -0.03 |
| EPS Diluted | -0.10 | -0.11 | -0.09 | -0.09 | -0.05 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.06 | -0.06 | -0.03 |
| Average Basic Shares Outstanding | 105.55M | 105.11M | 104.64M | 104.09M | 103.70M |
| Average Diluted Shares Outstanding | 105.55M | 105.11M | 104.64M | 104.09M | 103.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |